Mirum: To the Moon, or Just a Mild Case of Liver Luck?

by

Alright, settle in, folks. We’re talkin’ Mirum Pharmaceuticals (MIRM +2.79%). Their stock’s been climbin’ faster than a caffeinated squirrel. Doubled in a year! Now, I’ve seen a lot of bubbles in my time – tulip mania, dot-coms, Beanie Babies – but this…this might be different. Might. Don’t go mortgaging the house just yet. But I’m tellin’ ya, 2026 could be…interesting. And by interesting, I mean potentially lucrative. Or a complete disaster. It’s biotech, what do you expect, a guarantee?

An Inflection Point? More Like a Bend in the Bile Duct!

They’re sayin’ Mirum is at an “inflection point.” Fancy words, folks. What it means is they actually made some money from operations in 2025. Cash flow! Can you believe it? In biotech, that’s like finding a unicorn that pays taxes. They also snagged two FDA approvals. Ctexli for this rare thing called cerebrotendinous xanthomatosis – try saying that after a few martinis – and a tablet form of Livmarli for another rare liver condition. Look, I’m not a doctor, I play one on the internet, but rare diseases are good business. Fewer competitors, desperate patients…it’s the circle of life, folks, the liver circle of life.

Loading widget...

And then, boom, they bought Bluejay Therapeutics. Added brelovitug to their pipeline. Sounds like a villain from a Bond movie, doesn’t it? But it’s a drug targeting hepatitis delta. Apparently, your liver can get viruses too. Who knew? Livmarli sales jumped 69% last year! Sixty-nine! Nice. Cholbam and Ctexli are up 31%. They’re predictin’ $630-650 million in revenue this year. That’s a lotta livers bein’ happy, folks. A lotta.

Multiple Catalysts? More Like a Fireworks Display of Hope!

Now, 2026. Oh boy. They’re lookin’ at a Phase 2B study for volixibat, treatin’ primary sclerosing cholangitis. Sounds unpleasant, doesn’t it? They’re hopin’ for accelerated approval. “Accelerated” is a good word. I like fast. If this drug works, it could be a blockbuster. No competition! That’s like showin’ up to a pie-eatin’ contest where everyone else brought forks. They’re also testin’ volixibat for another liver thing, primary biliary cholangitis. Enrollment’s expected in the second half of the year. They’re busy, these Mirum folks. Very busy. They’re practically runnin’ a liver convention.

And if that wasn’t enough, they’ve got results from a Phase 3 study of brelovitug comin’ in the second half. Positive data means they can file for approval in early 2027. They’re movin’ fast, folks, faster than a liver cell dividin’. They’ve even sped up a Phase 3 study for Livmarli. Enrollment in the first half of 2026, data before the end of the year. They’re practically givin’ away drugs at this point!

So, will Mirum’s stock keep climbin’ in 2026? Look, I’m not a fortune teller, I’m an investor who’s seen a few things. But the odds look pretty good. But remember, folks, this is biotech. It’s a gamble. A beautiful, potentially lucrative gamble. And if it all goes south? Well, at least we had a good story, right? Now, if you’ll excuse me, I need a liver cleanse…and a stiff drink.

Read More

2026-01-27 11:02